Company: Denali Therapeutics
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s Disease
Mechanism Type: Neuroprotection, Necroptosis Blocker
Mechanism: A RIPK1 kinase inhibitor. This drug aims to protect motor neurons by blocking necroptosis, which may destroy motor neurons in ALS. The approach may also reduce neuroinflammation.
U.S. Status for ALS: Phase I
 Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis ClinicalTrials.gov, 28 Nov 2018. Accessed 25 Jan 2019 from https://clinicaltrials.gov/ct2/show/NCT03757351.
 RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Ito, Y. et al. Science. 2016 Aug 5;353(6299):603-8.
Last updated February 8th, 2018